What is Zacks Small Cap’s Forecast for QNRX Q1 Earnings?

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for shares of Quoin Pharmaceuticals in a research note issued to investors on Monday, March 17th. Zacks Small Cap analyst M. Marin forecasts that the company will post earnings per share of ($0.11) for the quarter. The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share. Zacks Small Cap also issued estimates for Quoin Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.15.

Quoin Pharmaceuticals Stock Down 3.2 %

Shares of NASDAQ:QNRX opened at $0.29 on Wednesday. The stock has a market cap of $1.46 million, a PE ratio of -0.07 and a beta of 1.82. The company’s fifty day moving average is $0.36 and its 200 day moving average is $0.55. Quoin Pharmaceuticals has a 52 week low of $0.27 and a 52 week high of $1.57.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Apollon Wealth Management LLC purchased a new position in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $52,000. Boothbay Fund Management LLC purchased a new position in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $53,000. Renaissance Technologies LLC raised its holdings in shares of Quoin Pharmaceuticals by 244.1% during the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after purchasing an additional 94,431 shares during the last quarter. Finally, Altium Capital Management LLC purchased a new position in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $184,000. 8.63% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Anthony James Culverwell bought 100,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were purchased at an average price of $0.45 per share, with a total value of $45,000.00. Following the purchase, the director now owns 100,317 shares of the company’s stock, valued at approximately $45,142.65. This trade represents a 31,545.74 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Gordon Dunn acquired 122,221 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $0.45 per share, for a total transaction of $54,999.45. Following the purchase, the chief financial officer now directly owns 151,077 shares of the company’s stock, valued at $67,984.65. This represents a 423.55 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 777,777 shares of company stock valued at $350,000 in the last quarter. Insiders own 3.70% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.